Clinical Trials

78 enrolled

Neoplasm Metastasis, Neoplasms

NCT05372614 2026-03-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase 1 Suspended

33 enrolled

Neoplasm Metastasis

NCT05687110 2026-03-18

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

43 enrolled

Neoplasm Metastasis

NCT05687136 2026-03-18

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

66 enrolled

Neoplasm Metastasis

NCT05691517 2026-03-18

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

35 enrolled

Neoplasm Metastasis

NCT05719558 2026-03-18

A Study of ASP1002 in Adults for Treatment of Solid Tumors

210 enrolled

Neoplasm Metastasis, Neoplasms

NCT06298357 2026-03-18

Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation

11 enrolled

Neoplasms

NCT06606990 2026-03-18

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

40 enrolled

Neoplasm Metastasis

NCT04585958 2026-03-17

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

55 enrolled

Neoplasm Metastasis

NCT04958239 2026-03-17

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

151 enrolled

Neoplasms

NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

24 enrolled

Neoplasm Metastasis

NCT05887882 2026-03-16

PNOC028

24 enrolled

Neoplasms

NCT06150157 2026-03-16

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

220 enrolled

Neoplasms

NCT06540066 2026-03-16

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

35 enrolled

Neoplasm Metastasis

NCT06997029 2026-03-16

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

234 enrolled

Neoplasms

NCT07030712 2026-03-16

MK-8294-001

67 enrolled

Neoplasm Metastasis, Neoplasms

NCT07474168 2026-03-16

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

9 enrolled

Neoplasms

NCT05935098 2026-03-13

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

Phase 1 Terminated

99 enrolled

Neoplasm Metastasis

NCT06178614 2026-03-13

A Study of JNJ-87890387 for Advanced Solid Tumors

200 enrolled

Neoplasms

NCT07454031 2026-03-13

Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma

22 enrolled

Neoplasm Metastasis, Neoplasms

NCT05557045 2026-03-12

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

332 enrolled

Neoplasm Metastasis

NCT03366116 2026-03-09

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

65 enrolled

Neoplasms

NCT05707910 2026-03-09

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

6 enrolled

Neoplasms

NCT02423057 2026-03-06

Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors

27 enrolled

Neoplasms

NCT06555744 2026-03-06

A Study of ZW191 in Participants With Solid Tumors

145 enrolled

Neoplasms

NCT07455617 2026-03-06

Study of ABO2102 in KRAS-Mutated Solid Tumors

101 enrolled

Neoplasm Metastasis

NCT06713369 2026-03-04

AZD5305

8 enrolled

Neoplasm Metastasis, Neoplasms

NCT06803680 2026-03-04

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

90 enrolled

Neoplasm Metastasis

NCT03391778 2026-03-03

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

250 enrolled

Neoplasms

NCT07046559 2026-03-03

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants

104 enrolled

Neoplasms

NCT05382559 2026-03-02

A Study of ASP3082 in Adults With Advanced Solid Tumors

681 enrolled

Neoplasm Metastasis, Neoplasms

NCT06884618 2026-03-02

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

345 enrolled

Neoplasms

NCT07269080 2026-03-02

STM-06

28 enrolled

Neoplasm Metastasis

NCT04294628 2026-02-27

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

62 enrolled

Neoplasm Metastasis

NCT06389123 2026-02-27

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

40 enrolled

Neoplasm Metastasis

NCT06759649 2026-02-27

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

200 enrolled

Neoplasms

NCT07438782 2026-02-27

First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors

97 enrolled

Neoplasms

NCT06521554 2026-02-25

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

200 enrolled

Neoplasm Metastasis

NCT07156136 2026-02-25

Study of IMC-P115C in Advanced PRAME-Positive Cancers

140 enrolled

Neoplasms

NCT00750841 2026-02-23

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

64 enrolled

Neoplasm Metastasis

NCT06959706 2026-02-20

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

50 enrolled

Carcinoma, Neoplasms

NCT05396833 2026-02-19

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

120 enrolled

Neoplasm Metastasis

NCT03964233 2026-02-18

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

119 enrolled

Neoplasms

NCT06524570 2026-02-18

iFOCUS

24 enrolled

Neoplasm Metastasis, Neoplasms

NCT06311578 2026-02-13

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

96 enrolled

Neoplasms

NCT07403721 2026-02-11

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

464 enrolled

Neoplasm Metastasis

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

35 enrolled

Neoplasm Metastasis

NCT01534598 2026-02-10

FdCyd and THU for Advanced Solid Tumors

59 enrolled

Neoplasms

NCT06607939 2026-02-10

OR2-01

36 enrolled